These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 28850705)

  • 21. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
    Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
    Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
    Schwartz JB; Kane L; Moore K; Wu AH
    J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of Akaike information criterion to evaluate warfarin dosing algorithm.
    Harada T; Ariyoshi N; Shimura H; Sato Y; Yokoyama I; Takahashi K; Yamagata S; Imamaki M; Kobayashi Y; Ishii I; Miyazaki M; Kitada M
    Thromb Res; 2010 Sep; 126(3):183-90. PubMed ID: 20553802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
    Moreau C; Pautas E; Gouin-Thibault I; Golmard JL; Mahé I; Mulot C; Loriot MA; Siguret V
    J Thromb Haemost; 2011 Apr; 9(4):711-8. PubMed ID: 21255252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
    Biss TT; Kamali F
    Pharmacogenomics; 2012 Aug; 13(11):1211-4. PubMed ID: 22920389
    [No Abstract]   [Full Text] [Related]  

  • 26. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
    Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
    J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic and clinical factors relating to warfarin dosing.
    Jonas DE; McLeod HL
    Trends Pharmacol Sci; 2009 Jul; 30(7):375-86. PubMed ID: 19540002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
    Ellis DJ; Usman MH; Milner PG; Canafax DM; Ezekowitz MD
    Circulation; 2009 Sep; 120(12):1029-35, 2 p following 1035. PubMed ID: 19738136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population.
    Pavani A; Naushad SM; Mishra RC; Malempati AR; Pinjala R; Kumar TR; Kutala VK
    Pharmacogenomics; 2012 Jun; 13(8):869-78. PubMed ID: 22676192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.
    Zambon CF; Pengo V; Moz S; Bozzato D; Fogar P; Padoan A; Plebani M; Groppa F; De Rosa G; Padrini R
    Eur J Clin Pharmacol; 2018 May; 74(5):571-582. PubMed ID: 29396738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 35. Warfarin therapy--why one dose does not fit all!
    Kulkarni V; Bhave A; Munshi RK; Bhalerao S; Bhattad D; Khude S; Upase D
    J Assoc Physicians India; 2013 Aug; 61(8):571-3. PubMed ID: 24818346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.
    Ferrari M; Pengo V; Barolo M; Bezzo F; Padrini R
    Eur J Clin Pharmacol; 2017 Jun; 73(6):699-707. PubMed ID: 28382498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive.
    Grice GR; Milligan PE; Eby C; Gage BF
    J Thromb Haemost; 2008 Jan; 6(1):207-9. PubMed ID: 17944998
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients.
    Yoshizawa M; Hayashi H; Tashiro Y; Sakawa S; Moriwaki H; Akimoto T; Doi O; Kimura M; Kawarasaki Y; Inoue K; Itoh K
    Thromb Res; 2009 Jun; 124(2):161-6. PubMed ID: 19135231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnosis and treatment of warfarin resistance].
    Tan S; Zhou X; Li Z; Zhang W; Liu Z; Zhou H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 38(3):313-7. PubMed ID: 23545828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
    Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
    Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.